OBJECTIVE: Our objective was to study in vivo biological effects of natalizumab on immune cell phenotype and function in multiple sclerosis (MS) patients. METHODS: Blood was obtained before and after serial monthly natalizumab infusions to track functional expression of VLA-4 and migratory capacity of immune cells. The impact of infusion on activation thresholds of immune cells was evaluated. RESULTS: Preinfusion VLA-4 expression differed across immune cell subsets. Natalizumab significantly, albeit partially, diminished VLA-4 expression on circulating immune cells. Cell subsets were differentially affected. Treatment significantly decreased migratory capacity of immune cells, correlating well with changes in VLA-4 expression. Effects of a single dose were not saturating and did not persist through the monthly dose interval. Infusion effect varied across patients but was remarkably stable in individual patients, over multiple infusions. Treatment significantly modulated proliferative responses of immune cells. INTERPRETATION: To our knowledge, we provide first proof of concept that natalizumab diminishes migratory capacity of immune cells. Our prospective study further shows that effects of therapy likely (1) differ for distinct immune cell subsets, (2) are not sustained over current dose interval, (3) have unique profiles in individual patients, and (4) include modulation of activation threshold of immune cells. Monitoring these parameters could be relevant to ongoing safety and efficacy considerations.
OBJECTIVE: Our objective was to study in vivo biological effects of natalizumab on immune cell phenotype and function in multiple sclerosis (MS) patients. METHODS: Blood was obtained before and after serial monthly natalizumab infusions to track functional expression of VLA-4 and migratory capacity of immune cells. The impact of infusion on activation thresholds of immune cells was evaluated. RESULTS: Preinfusion VLA-4 expression differed across immune cell subsets. Natalizumab significantly, albeit partially, diminished VLA-4 expression on circulating immune cells. Cell subsets were differentially affected. Treatment significantly decreased migratory capacity of immune cells, correlating well with changes in VLA-4 expression. Effects of a single dose were not saturating and did not persist through the monthly dose interval. Infusion effect varied across patients but was remarkably stable in individual patients, over multiple infusions. Treatment significantly modulated proliferative responses of immune cells. INTERPRETATION: To our knowledge, we provide first proof of concept that natalizumab diminishes migratory capacity of immune cells. Our prospective study further shows that effects of therapy likely (1) differ for distinct immune cell subsets, (2) are not sustained over current dose interval, (3) have unique profiles in individual patients, and (4) include modulation of activation threshold of immune cells. Monitoring these parameters could be relevant to ongoing safety and efficacy considerations.
Authors: Niannian Ji; Nagarjun Rao; Neal M Guentzel; Bernard P Arulanandam; Thomas G Forsthuber Journal: J Immunol Date: 2011-01-26 Impact factor: 5.422
Authors: Spyridon Chalkias; Xin Dang; Evelyn Bord; Marion C Stein; R Philip Kinkel; Jacob A Sloane; Maureen Donnelly; Carolina Ionete; Maria K Houtchens; Guy J Buckle; Stephanie Batson; Igor J Koralnik Journal: Ann Neurol Date: 2014-06-10 Impact factor: 10.422
Authors: Phillip J Stewart-Hutchinson; Taylor P Szasz; Emily R Jaeger; Michael D Onken; John A Cooper; Sharon Celeste Morley Journal: J Leukoc Biol Date: 2017-06-21 Impact factor: 4.962
Authors: Marco A Lima; Angela Marzocchetti; Patrick Autissier; Troy Tompkins; Yiping Chen; Jennifer Gordon; David B Clifford; Rajesh T Gandhi; Nagagopal Venna; Joseph R Berger; Igor J Koralnik Journal: J Virol Date: 2007-01-17 Impact factor: 5.103
Authors: L Shinto; G Marracci; S Baldauf-Wagner; A Strehlow; V Yadav; L Stuber; D Bourdette Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2009-01-25 Impact factor: 4.006
Authors: J Sellner; W Koczi; A Harrer; K Oppermann; E Obregon-Castrillo; G Pilz; P Wipfler; S Afazel; E Haschke-Becher; E Trinka; J Kraus Journal: Clin Exp Immunol Date: 2013-09 Impact factor: 4.330